A comparison of the @entity137 and tolerability of two intraperitoneal chemotherapy regimens for XXXX .

@entity43 @entity1 @entity137 @entity390 @entity3003 @entity16 @entity900 @entity1311 @entity391 @entity1503 @entity1398 @entity902 @entity1349
OBJECTIVES: Randomized controlled trials (RCTs) in optimally cytoreduced @entity43 ( @entity43 ) @entity1 have demonstrated an impressive survival benefit of intraperitoneal (IP) @entity902 over intravenous (IV), but its use has been limited by significant @entity137 from @entity900 . The aim of this study was to compare the @entity137 and tolerability of IP @entity900 to IP @entity3003 in @entity1 with optimally cytoreduced @entity43 . METHODS: Retrospective analysis of 141 @entity1 with @entity43 who underwent optimal surgical cytoreduction followed by IV @entity1311 and IP @entity900 or IP @entity3003 was performed. @entity137 of the two treatment regimens were compared. As a secondary outcome, @entity1349 ( @entity1349 ) and progression-free survival (PFS) probabilities were obtained using the Kaplan-Meier estimate; the log-rank test was used to compare survival curves. RESULTS: Of the 141 @entity1 , 77 (54.6%) received IP @entity900 and 64 (45.4%) received IP @entity3003 . Eighty-six percent received at least 4cycles of IP chemotherapy. IP @entity900 was associated with significantly more grade 3 @entity390 and @entity391 (10.4% vs 1.6%, p=0.033), grade 3 @entity16 (7.8% vs 0%, p=0.013) and grade 2-3 @entity1398 (22.1% vs 9.4%, p=0.042). No difference in PFS (p=0.602) or @entity1349 (p=0.107) was found between the groups. CONCLUSION: IP chemotherapy had a high completion rate in both groups of @entity1 . IP @entity3003 required a less resource intense protocol and was tolerated better than IP @entity900 with less @entity1503 .
